Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 3.9% year on ...

It's been a mediocre week for Artivion, Inc. ( NYSE:AORT ) shareholders, with the stock dropping 13% to US$25.42 in ...

Artivion (NYSE:AORT – Get Free Report) had its target price reduced by equities research analysts at Stifel Nicolaus from $33 ...

Artivion (AORT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

Artivion, Inc. (NYSE:AORT – Get Free Report)’s stock price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $27.85, ...

Stifel lowered the firm’s price target on Artivion (AORT) to $30 from $33 and keeps a Buy rating on the shares after Q4 consensus sales ...

The Kennesaw, Georgia-based company said it had a loss of 39 cents per share. Earnings, adjusted for one-time gains and costs, were less than 1 cent on a per-share basis. The biological medical device ...

Greetings and welcome to the Artivion fourth-quarter and year-end 2024 financial conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to ...

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Artivion (AORT – Research Report), with a price target ...

Medical device company ICU Medical (NASDAQ:ICUI) will be reporting results tomorrow after market close. Here’s what you need ...

Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% ...

ATLANTA - Artivion, Inc. (NYSE: AORT) saw its shares plunge 10% after-hours Monday after the cardiac and vascular surgery company reported fourth quarter revenue that fell short of analyst ...